Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hitting HIV's Harpoon.

Marit J van Gils1, Rogier W Sanders2

  • 1Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands.

Immunity
|July 19, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early immune events during SARS-CoV-2 infection impact memory T and B cell responses.

Communications biology·2026
Same author

High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies.

NPJ vaccines·2026
Same author

Enhanced Human Antigen-Specific B Cell Responses Using In Vitro 3D Tonsil Cultures Containing Stromal Cells.

Advanced healthcare materials·2026
Same author

Genetically diverse influenza antibodies highlight the role of IG germline gene variation and inform population-comprehensive vaccine strategies.

Immunity·2026
Same author

SARS-CoV-2 crossreactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic.

Npj viruses·2026
Same author

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination.

European journal of immunology·2026
Same journal

Targeting cholesterol esterification sensitizes liver cancer to CD8<sup>+</sup> T cell attack by impairing metabolic and redox resilience.

Immunity·2026
Same journal

Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.

Immunity·2026
Same journal

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Immunity·2026
Same journal

B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection.

Immunity·2026
Same journal

Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion.

Immunity·2026
Same journal

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Immunity·2026
See all related articles

Researchers developed a novel vaccination strategy targeting the HIV-1 fusion peptide. This approach successfully generated antibodies in animal models capable of neutralizing a wide range of HIV-1 strains.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • The human immunodeficiency virus type 1 (HIV-1) fusion peptide is a critical component of viral entry and a recognized target for broadly neutralizing antibodies.
  • Developing effective vaccines against HIV-1 remains a significant global health challenge due to the virus's high mutation rate and complex envelope structure.

Purpose of the Study:

  • To investigate the potential of a sequential vaccination strategy using the HIV-1 fusion peptide followed by an envelope glycoprotein trimer.
  • To determine if this approach can elicit broadly neutralizing antibodies against diverse HIV-1 strains in animal models.

Main Methods:

  • Animal models were vaccinated sequentially: first with a fusion peptide antigen, then with an HIV-1 envelope glycoprotein trimer.
  • Antibody responses were analyzed for their breadth and neutralizing capacity against a panel of diverse HIV-1 isolates.

Related Experiment Videos

Main Results:

  • The sequential vaccination regimen successfully induced antibodies in the animal models.
  • These induced antibodies demonstrated the ability to neutralize a diverse range of HIV-1 viruses, indicating broad efficacy.

Conclusions:

  • This study provides proof-of-concept for a novel vaccination strategy targeting the HIV-1 fusion peptide.
  • The findings suggest that this approach holds promise for developing vaccines that can elicit broadly neutralizing antibodies against HIV-1.